Lincoln Pharmaceuticals Ltd · NSE:LINCOLN
Lincoln Pharmaceuticals — Q2 FY2021 Earnings Presentation
20 slides from Lincoln Pharmaceuticals's earnings presentation, 2020
Slide 1: Q2 FY2021 Earnings Presentation
Q2 FY2021 Earnings Presentation GROWING IS COMMITMENT. WE POSSESS. P H A R M A C E U T IC A L S LT D . H E ALTH C A R E F O R A L L www.lincolnpharma.com 1
Slide 2: Highlights
Highlights Management Perspective Q2 FY2021 vs. Q2 FY2020 “Lincoln Pharma continued to deliver a robust performance during the o Total Income of Rs. 1,267 million, up 9.9% quarter, supported by strong market demand and improved business performance across geographies. Our export business improved o
Slide 3: Performance Overview
Performance Overview Consolidated Financial Performance Q2 y-o-y Q1 q-o-q H1 y-o-y Particulars (mn.) FY2021 FY2020 Growth (%) FY2021 Growth (%) FY2021 FY2020 Growth (%) Net Revenue 1,267 1,152 9.9% 1056 20.0% 2323 2133 8.9% EBITDA 304 272 11.6% 240 26.7% 543 475 14.3% Margin (%) 24.0% 23.6% 22.7% 23
Slide 4: Performance Overview: Revenue Breakup
Performance Overview Revenue Breakup 4% 2% 3% 2% General Anti Infectives 9% 24% 22.2% Respiratory Systems 23.9% 25.8% Therapeutic Area 36.1% 14% Alimentary Tract and Metabolism 0.1% Genito Urinary System and Sex Hormones Q2 FY21 2.9% 13% Q2 FY20 15% Musculo-Skeletal System 7.3% 0.2% 14% Parasitology
Slide 5: Performance Trend
Performance Trend Total Income (Rs. million) and Y-o-Y Growth (%) EBITDA (Rs. million) and Margin (%) 23.6% 24.0% 22.7% 19.7% 7.6% 5.4% 7.6% 9.9% 16.0% 15.5% 1,152 1,016 827 1,056 1,267 272 162 128 240 304 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 PBT (Rs. milli
Slide 6: Performance Trend
Performance Trend Total Debt / LTM EBITDA Total Debt / Net Worth 0.54x 0.12x 0.25x 0.06x 0.22x 0.04x 0.18x 0.02x 0.06x 0.01x Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q3 FY20 Q4 FY20 Q1 FY21 Q2 FY21 ROCE1 RONW2 21.1% 21.8% 21.3% 16.5% 17.0% 16.4% 16.5% 16.1% 19.3% 20.7% Q2 FY20 Q3 FY20 Q4 FY20
Slide 7: Leverage Profile
Leverage Profile (Rs. million) Sep-20 Mar-20 Credit Rating Long Term Debt 3.4 8.5 o CRISIL ▪ Long term rating: A-/Stable Short Term Debt 178.4 38.3 ▪ Short term rating: A2+ Total Debt 181.8 46.8 o ICRA Less: Cash & Cash Equivalents 307.6 122.3 ▪ Long term rating: A-/Stable to A-/Positive Net Debt /
Slide 8: Recent Developments
Recent Developments Secured a patent for Diclofenac Rectal Spray International operations • Recently the company has been awarded with a patent for its liquid Diclofenac Metered- • Aggressively started the business in Francophone African countries and some of the Dose Rectal Spray (Diclofenac Rectal
Slide 9: Research & Development
Research & Development Research Facilities R&D Expenditure (Rs. mn) and as % of Sales 4.0% 3.6% 3.2% 2.4% 2.0% 2.7% 148.1 135.1 Senior Scientist 15 117.3 Junior Scientist 18 1.6% 88.5 Analysts 18 72.6 79.5 Regulatory Personnel 12 Administrative Personnel 9 34.3 Others 6 Total 78 FY14 FY15 FY16 FY17
Slide 10: A Leading Pharmaceutical Company
A Leading Pharmaceutical Company Research & Development Department Market Presence Presence in Presence in 7 Patents granted 1,700 Registered products 60+ 26 25 Patents applications 700 in pipeline Countries States across India 600+ 72nd 15+ Formulations developed Rank in AIOCD Therapeutic areas 650
Slide 11: Key Milestones
Key Milestones 1 MW Solar roof top plant Received WHO – Becomes Public Launch 3 products which are installed Covered 80% Developed & GMP for plant / Limited Company Installed Windmill first time in India. Entered in of all India launched 2 more production unit from a Partnership 600 KVA more (regula
Slide 12: Global Footprint
Global Footprint Presence over 60 + Countries in Europe, Latin America, Africa, Asia Pacific, South East Asia and 26 States across India Europe: France South & Central Asia : Afghanistan, Armenia, America : Bolivia, Africa: Angola, Benin, Botswana, Azerbaijan, Bhutan, Cambodia, Chile, Costa Rica, Bu
Slide 13: Best in Class Facilities
Best in Class Facilities Certifications: WHO-GMP Certified; ISO 9001:2015 Certified R&D Center: Approved by Government of India; Team of 30 scientists for R&D Green Energy: Windmill project for captive consumption Dosage Forms Produced at Unit 1 Dosage Forms Produced at Unit 2 Description Annual Cap
Slide 14: Wide Spectrum of Therapeutic Coverage
Wide Spectrum of Therapeutic Coverage Cough Cough&&Cold Cold// Sterile SterileOphthalmic Ophthalmic Dermatologist Dermatologist Gyneacologial Gyneacologial Gastro GastroIntestinal Intestinal Anti AntiAllergic Allergic// Eye Eye Preparation Preparation Products Products Range Range Anti-asthmatics An
Slide 15: Key Brands
Key Brands Domestic Market International Market Calcium Carbonate 1250 mg+ 11 Antioxidants + 33 Essential Micronutrients + Each squirts (spray) delivers 2 α-β Arteether Injection Vit. D3 250 I.U. Tablets 5 Amino Acids mg Ondansetron Hydrochloride 150mg/ 2 ml Effective Anti- Malarial Kingping Heparin
Slide 16: Recent Launches
Recent Launches o Progesterone spray • Unique delivery system for accurate 25mg delivery of micronized progesterone/Spray • Formulation dispensed in mist form which provides local as well as systemic effect of Progesterone via vaginal route covering large area of vaginal cavity • Better patient comp
Slide 17: Recent Launches
Recent Launches o Domi Up Spray • Meter dose pump • Each squirt (spray) accurately delivers 2 mg Ondansetron Hydrochloride • Faster onset of action • Prompt relief from nausea & vomiting • Convenient for patient over Injectable • Better patients compliance o Namcold DX • First time in India: ‘Extend
Slide 18: Recent Launches
Recent Launches o USP INFITY - YS • Most stable derivative of Vitamin C (at 450C) • Easy to penetrate skin • Molecular weight of Hyaluronic acid in INFITY – YS is equivalent to 1000 KDal o USP INFITY - HS • Revitalized the DPC • Covering all aspects of Baldness in one solution • Powered with the Hai
Slide 19: Disclaimer
Disclaimer This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Lincoln Pharmaceuticals’ future business developments and economic perfor
Slide 20: Corporate Office
CORPORATE OFFICE LINCOLN HOUSE B/h. Satyam Complex, Science City Road, Sola, Ahmedabad – 380 060. Gujarat, INDIA. Phone: +91-79-41078000 • Fax: +91-79-41078062 E-mail: [email protected] • Web: www.lincolnpharma.com CIN: L24230GJ1995PLC024288 KP Sompura Ajay Tambhale / Bopiah Ganapathy Finance H
Lincoln Pharmaceuticals — Q2 FY2021 Earnings Presentation on 6ix